FBT241220P184000
- 0.00
- 0.000.00%
First Trust Exchange Traded Fund Nyse Arca Biotechnology Index Fund Newsroom
Incyte Gains Amid Takeover Speculation
Trump's R&D policy ignites cash flow! These companies welcome a "financial spring"!
Trump's new policy on research and development may bring a "cash flow revolution" to usa companies! By allowing companies to record research and development expenses instantly, businesses can not only reduce their tax burden but also significantly enhance their liquidity.
Looking At Gilead Sciences's Recent Unusual Options Activity
European Stocks Will See Downtrend Mid-year 2025 Before Recovery
Screening For Black Friday Bargains In The Stock Market
The hidden winner in the USA election? Cathie Wood's ARKK hit a new high for the year, all thanks to these heavily weighted stocks!
The strong rise of ARKK is mainly attributed to the increase in its heavy holdings, Tesla, and cryptos-related companies, Coinbase and Robinhood.
Gilead Sciences Ticks Upward for the Eight Consecutive Session
Looking Into Natera's Recent Short Interest
Trump has promised to significantly reduce corporate taxes! Who are the potential big winners of the tax cuts?
JPMorgan pointed out that companies in the S&P 500 index with an actual tax rate greater than 15% and 80% of revenue coming from the USA are potential beneficiaries of Trump's tax cuts policy, mainly concentrated in the financial and industrial sectors, followed by essential consumer, optional consumer, and medical care sectors.
Short Stock Ideas From Each Sector With Earnings Quality in the Bottom 20%
Natera Announces Its Prospera Lung Test Has Met Coverage Requirements From The Centers For Medicare & Medicaid Services' Molecular Diagnostics Services Program For Single Lung Transplant Recipients; This Coverage Applies To SLT Patients In The...
Trump Taps Jay Bhattacharya to Lead National Institutes of Health
Acadia Signs Licensing Deal for Essential Tremor Drug Candidate
Acadia Pharmaceuticals Announces Exclusive License Agreement With Saniona For SAN711; Under The Terms Of The License Agreement, Saniona Will Receive $28M Upfront Plus Potential Milestone Payments Of Up To $582M
Exelixis Provides Regulatory Update Related To Supplemental New Drug Application For Cabozantinib; Alliance For Clinical Trials In Oncology Independent Data And Safety Monitoring Board Recommends Trial Enrollment To Be Stopped
Wolfe's Most Shorted 'Hit List' – FSLR, BE, WBA, SJM
Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages
Guardant Health Shares Are Trading Higher After a Jury Issued a Decision in the Company's Favor Regarding a False Advertising Case Filed by Natera Concerning Statements Made About Guardant's Reveal Test.
Natera Issues Statement On Guardant Health Litigation; Says "A Jury Issued A Decision In Guardant's Favor. We Disagree With This Decision And Will Ask The Court To Overturn It"
Gilead Acquires Investigational HIV Vaccine From Spanish Biotech Aelix